/

Other

/

Neurocrine Biosciences

Neurocrine Biosciences

Neurocrine Biosciences

Verified Nov 2026

Other

·

United States flag

San Diego, California

·

Since 1992

Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and headquartered in San Diego, California, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops FDA-approved treatments and investigational therapies for neurological, neuroendocrine, and neuropsychiatric disorders, serving patients with movement disorders and rare pediatric epilepsies. The company acquired Soleno Therapeutics in 2026 to expand into metabolic and endocrine rare diseases.

Neurocrine Biosciences

Verified Nov 2026

AT A GLANCE

Founded

1992

Headquarters

United States flag

San Diego, California

Employees

1,000-5,000

Ownership

Neurocrine Biosciences at a glance

Revenue

$1-5B

Est. band

Employees

1,000-5,000

Founded

1992

Headquarters

San Diego, California

Import activity

3

Industries

Automotive

Electric Vehicles

Medical

Sourcing and import activity

From US customs bill-of-lading records

US sea imports

3

Named foreign suppliers

3

Top origins

Italy · Germany · Netherlands

Chart of the supplier's US import shipment volume trend over time

Shared foreign counterparties do not establish that these companies buy from Neurocrine Biosciences.

What this tells a buyer

Neurocrine received exclusive worldwide rights to SCO-483, a selective melanocortin 2 receptor antagonist, in April 2026, and completed a $2.9 billion acquisition of Soleno Therapeutics in the same month to broaden its rare disease portfolio.

The company markets four FDA-approved treatments in the United States, including INGREZZA for tardive dyskinesia and dyskinetic cerebral palsy, with an active pipeline of investigational therapies.

Neurocrine maintains a supply chain spanning Europe, with documented shipments from suppliers in Italy, Germany, Switzerland, and the Netherlands.

Source: US customs bill-of-lading records and public filings · Last verified Nov 16, 2026

STABILITY SIGNALS

Established & active

34 years in operation (founded 1992).

3 US import shipments on record.

Overview

Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and headquartered in San Diego, California, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops FDA-approved treatments and investigational therapies for neurological, neuroendocrine, and neuropsychiatric disorders, serving patients with movement disorders and rare pediatric epilepsies. The company acquired Soleno Therapeutics in 2026 to expand into metabolic and endocrine rare diseases.

At a glance

Attribute

Detail

Founded

1992

Headquarters

San Diego, California

Employees

1,000-5,000

Revenue

$1-5B (estimated)

What Neurocrine Biosciences makes

The company markets four FDA-approved treatments in the United States, including INGREZZA for tardive dyskinesia and dyskinetic cerebral palsy, with an active pipeline of investigational therapies.

Trade and customs footprint

Neurocrine received exclusive worldwide rights to SCO-483, a selective melanocortin 2 receptor antagonist, in April 2026, and completed a $2.9 billion acquisition of Soleno Therapeutics in the same month to broaden its rare disease portfolio. US customs bill-of-lading records list 3 inbound shipments across 3 foreign suppliers, with top origins including Italy · Germany · Netherlands.

Latest developments

Facilities

Neurocrine Biosciences is headquartered in San Diego, California. Public sources also reference these locations:

Company details

Neurocrine maintains a supply chain spanning Europe, with documented shipments from suppliers in Italy, Germany, Switzerland, and the Netherlands. Neurocrine Biosciences was founded in 1992, has an estimated 1,000-5,000 employees, and is headquartered in San Diego, California. On the LightSource stability read it is rated "Established & active": 34 years in operation (founded 1992). 3 US import shipments on record.

Frequently asked questions

What does Neurocrine Biosciences do?

Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and headquartered in San Diego, California, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops FDA-approved treatments and investigational therapies for neurological, neuroendocrine, and neuropsychiatric disorders, serving patients with movement disorders and rare pediatric epilepsies. The company acquired Soleno Therapeutics in 2026 to expand into metabolic and endocrine rare diseases.

Where is Neurocrine Biosciences headquartered?

Neurocrine Biosciences is headquartered in San Diego, California (6027 Edgewood Bend Ct, San Diego, California, 92130-8235).

When was Neurocrine Biosciences founded?

Neurocrine Biosciences was founded in 1992.

How big is Neurocrine Biosciences?

Neurocrine Biosciences has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).

Does Neurocrine Biosciences import from overseas suppliers?

US customs bill-of-lading records show 3 inbound shipments for Neurocrine Biosciences, with top origins including Italy · Germany · Netherlands.

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

San Diego, California (HQ)Headquarters · United States
San Diego, California (HQ)6027 Edgewood Bend Ct, San Diego, California, 92130-8235, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.